Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Number of participants with achievement of greater than or equal to (>=) 10 percent (%) body weight reduction (yes/no)

Measured as count of participants.

Time frame: From baseline (week 0) to end of treatment (week 64)

Number of participants with achievement of >= 15 % body weight reduction (yes/no)

Measured as count of participants.

Time frame: From baseline (week 0) to end of treatment (week 64)

Change in waist circumference

Measured as centimeters (cm).

Time frame: From baseline (week 0) to end of treatment (week 64)

Ratio to baseline in triglycerides

Measured as ratio.

Time frame: From baseline (week 0) to end of treatment (week 64)

Ratio to baseline in high sensitivity C-Reactive Protein (hsCRP)

Measured as ratio.

Time frame: From baseline (week 0) to end of treatment (week 64)

Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score

Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical function score ranges from 0-100.

Time frame: From baseline (week 0) to end of treatment (week 64)

Change in Systolic Blood Pressure (SBP)

Measured as millimeter of mercury (mmHg).

Time frame: From baseline (week 0) to end of treatment (week 64)

Change in body weight

Measured as kilograms (kg).

Time frame: From baseline (week 0) to end of treatment (week 64)

Number of participants with achievement of >= 5 % body weight reduction (yes/no)

Measured as count of participants.

Time frame: From baseline (week 0) to end of treatment (week 64)

Change in SF-36v2® Health Survey Acute (SF-36v2® Acute) physical component summary score

Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The physical component summary score ranges from 6.1 to 79.7.

Time frame: From baseline (week 0) to end of treatment (week 64)

Change in SF-36v2® mental component summary score

Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The mental component summary score ranges from -3.8 to 78.7.

Time frame: From baseline (week 0) to end of treatment (week 64)

Change in IWQOL-Lite-CT total score

Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The total score ranges from 0-100.

Time frame: From baseline (week 0) to end of treatment (week 64)

Number of participants with achievement of at least 14.6-point increase in IWQOL-Lite-CT Physical Function score (yes/no)

Measured as count of participants. IWQOL-Lite-CT measures weight related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical function score ranges from 0-100.

Time frame: From baseline (week 0) to end of treatment (week 64)

Change in Diastolic Blood Pressure (DBP)

Measured as mmHg.

Time frame: From baseline (week 0) to end of treatment (week 64)

Ratio to baseline of total cholesterol

Measured as ratio.

Time frame: From baseline (week 0) to end of treatment (week 64)

Ratio to baseline of High-Density Lipoprotein (HDL) cholesterol

Measured as ratio.

Time frame: From baseline (week 0) to end of treatment (week 64)

Ratio to baseline of Low-Density Lipoprotein (LDL) cholesterol

Measured as ratio.

Time frame: From baseline (week 0) to end of treatment (week 64)

Ratio to baseline of Very Low-Density Lipoprotein (VLDL) cholesterol

Measured as ratio.

Time frame: From baseline (week 0) to end of treatment (week 64)

Ratio to baseline of non-HDL cholesterol

Measured as ratio.

Time frame: From baseline (week 0) to end of treatment (week 64)

Ratio to baseline of free fatty acids

Measured as ratio.

Time frame: From baseline (week 0) to end of treatment (week 64)

Change in glycated haemoglobin (HbA1c) percentage-points (%-points)

Measured as %-points.

Time frame: From baseline (week 0) to end of treatment (week 64)

Change in HbA1c millimoles per mole (mmol/mol)

Measured as mmol/mol.

Time frame: From baseline (week 0) to end of treatment (week 64)

Change in Fasting Plasma Glucose (FPG) millimoles per litre (mmol/L)

Measured as mmol/L.

Time frame: From baseline (week 0) to end of treatment (week 64)

Change in FPG milligrams per deciliter (mg/dL)

Measured as mg/dL.

Time frame: From baseline (week 0) to end of treatment (week 64)

Ratio to baseline in fasting serum insulin

Measured as ratio.

Time frame: From baseline (week 0) to end of treatment (week 64)

Number of treatment emergent adverse events (TEAEs)

Measured as count of events.

Time frame: From baseline (week 0) to end of study (week 71)

Number of treatment emergent serious adverse events (TESAEs)

Measured as count of events.

Time frame: From baseline (week 0) to end of study (week 71)